survival. Nat Commun 7:13041. https://doi.
org/10.1038/ncomms13041
19. Koochekpour S, Marlowe T, Singh KK,
Attwood K, Chandra D (2013) Reduced mitochondrial DNA content associates with poor
prognosis of prostate cancer in African American men. PLoS One 8(9):e74688. https://doi.
org/10.1371/journal.pone.0074688
20. Guo J, Zheng L, Liu W, Wang X, Wang Z,
Wang Z, French AJ, Kang D, Chen L, Thibodeau SN, Liu W (2011) Frequent truncating
mutation of TFAM induces mitochondrial
DNA depletion and apoptotic resistance in
microsatellite-unstable colorectal cancer. Cancer Res 71(8):2978–2987. https://doi.org/
10.1158/0008-5472.CAN-10-3482
21. Weerts MJA, Sieuwerts AM, Smid M, Look
MP, Foekens JA, Sleijfer S, Martens JWM
(2016) Mitochondrial DNA content in breast
cancer: impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget 7
(20):29166–29176.
https://doi.org/10.
18632/oncotarget.8688
22. Jia D, Park JH, Jung KH, Levine H, Kaipparettu BA (2018) Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming
and hybrid metabolic states. Cell 7(3). https://
doi.org/10.3390/cells7030021
23. Dupuy F, Tabarie `s S, Andrzejewski S, Dong Z,
Blagih J, Annis Matthew G, Omeroglu A,
Gao D, Leung S, Amir E, Clemons M,
Aguilar-Mahecha A, Basik M, Vincent
Emma E, St.-Pierre J, Jones Russell G, Siegel
Peter M (2015) PDK1-dependent metabolic
reprogramming dictates metastatic potential
in breast cancer. Cell Metabol 22
(4):577–589.
https://doi.org/10.1016/j.
cmet.2015.08.007
24. Pelicano H, Zhang W, Liu J, Hammoudi N,
Dai J, Xu RH, Pusztai L, Huang P (2014)
Mitochondrial dysfunction in some triplenegative breast cancer cell lines: role of
mTOR pathway and therapeutic potential.
Breast Cancer Res 16(5):434. https://doi.
org/10.1186/s13058-014-0434-6
340
Sugandha Bhatia et al.
org/10.1038/ncomms13041
19. Koochekpour S, Marlowe T, Singh KK,
Attwood K, Chandra D (2013) Reduced mitochondrial DNA content associates with poor
prognosis of prostate cancer in African American men. PLoS One 8(9):e74688. https://doi.
org/10.1371/journal.pone.0074688
20. Guo J, Zheng L, Liu W, Wang X, Wang Z,
Wang Z, French AJ, Kang D, Chen L, Thibodeau SN, Liu W (2011) Frequent truncating
mutation of TFAM induces mitochondrial
DNA depletion and apoptotic resistance in
microsatellite-unstable colorectal cancer. Cancer Res 71(8):2978–2987. https://doi.org/
10.1158/0008-5472.CAN-10-3482
21. Weerts MJA, Sieuwerts AM, Smid M, Look
MP, Foekens JA, Sleijfer S, Martens JWM
(2016) Mitochondrial DNA content in breast
cancer: impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget 7
(20):29166–29176.
https://doi.org/10.
18632/oncotarget.8688
22. Jia D, Park JH, Jung KH, Levine H, Kaipparettu BA (2018) Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming
and hybrid metabolic states. Cell 7(3). https://
doi.org/10.3390/cells7030021
23. Dupuy F, Tabarie `s S, Andrzejewski S, Dong Z,
Blagih J, Annis Matthew G, Omeroglu A,
Gao D, Leung S, Amir E, Clemons M,
Aguilar-Mahecha A, Basik M, Vincent
Emma E, St.-Pierre J, Jones Russell G, Siegel
Peter M (2015) PDK1-dependent metabolic
reprogramming dictates metastatic potential
in breast cancer. Cell Metabol 22
(4):577–589.
https://doi.org/10.1016/j.
cmet.2015.08.007
24. Pelicano H, Zhang W, Liu J, Hammoudi N,
Dai J, Xu RH, Pusztai L, Huang P (2014)
Mitochondrial dysfunction in some triplenegative breast cancer cell lines: role of
mTOR pathway and therapeutic potential.
Breast Cancer Res 16(5):434. https://doi.
org/10.1186/s13058-014-0434-6
340
Sugandha Bhatia et al.